General MedicationsINTRADERMALStandard
ZINGO
LIDOCAINE HYDROCHLORIDE
Standard Dose
0.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ZINGO is listed in Drugs@FDA under application 022114 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LIDOCAINE HYDROCHLORIDE Form and strength SYSTEM;INTRADERMAL - 0.5MG Sponsor POWDER PHARMS Submission history Latest submission status date: 2025-12-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZINGO is listed in Drugs@FDA under application 022114 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LIDOCAINE HYDROCHLORIDE Form and strength SYSTEM;INTRADERMAL - 0.5MG Sponsor POWDER PHARMS Submission history Latest submission status date: 2025-12-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.